<DOC>
	<DOCNO>NCT01194154</DOCNO>
	<brief_summary>This randomize , single-blind , proof-of-concept study investigate protective effect early treatment Mircera participants chronic kidney disease renal disease progression . Participants randomly assign receive 30 microgram ( mcg ) Mircera subcutaneous injection monthly match placebo . Depending change hemoglobin value , dose Mircera adjust 50 mcg 75 mcg monthly . The anticipated time study treatment 24 month .</brief_summary>
	<brief_title>A Study Methoxy Polyethylene Glycol-epoetin Beta ( Mircera ) Participants With Chronic Kidney Disease ( PRIMAVERA )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>For diabetic participant : Type 2 diabetes mellitus glycated hemoglobin ( HbA1c ) great ( &gt; ) 7 % antidiabetic treatment For renal allograft recipient : Status least 6 month post transplantation Chronic kidney disease stage III Urinary albumintocreatinine ratio le ( &lt; ) 3000 milligram ( mg ) /gram ( g ) total protein &lt; 3000 mg/ 24 hour urine sample applicable Hemoglobinlevel &lt; 11 &gt; 14 g/deciliter ( dL ) Average systolic blood pressure ( SBP ) &gt; 140 millimeter mercury ( mm Hg ) average diastolic blood pressure ( DBP ) &gt; 90 mm Hg Initiation angiotensin convert enzyme inhibitor , angiotensin 2 receptor blocker aliskiren treatment le 3 month enrolment Present know iron deficiency HbA1c &gt; 9 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>